Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/16/22
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferencePRNewsWire • 02/10/22
Protagonist Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/04/22
Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual MeetingPRNewsWire • 12/12/21
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology SummitPRNewsWire • 12/03/21
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple IndicationsPRNewsWire • 12/02/21
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary HemochromatosisPRNewsWire • 11/15/21
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor ConferencesPRNewsWire • 11/11/21
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual MeetingPRNewsWire • 11/04/21
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/03/21
Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 11/03/21
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins ListBenzinga • 11/01/21
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with JanssenPRNewsWire • 10/26/21
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of MergerBenzinga • 10/25/21
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics SummitPRNewsWire • 10/12/21
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering TodayInvestorPlace • 10/11/21
Protagonist Therapeutics shares soar after FDA lifts clinical hold on its experimental cancer drugMarket Watch • 10/11/21